—By Amba Kak, Sarah Myers West and Meredith Whittaker, members of the AI Now Institute

Till late November, when the epic saga of OpenAI’s board breakdown unfolded, the informal observer might be forgiven for assuming that the ecosystem round generative AI was vibrant and aggressive.

However this isn’t the case—nor has it ever been. And understanding why is key to understanding what AI is, and what threats it poses. Put merely, within the context of the present paradigm of constructing larger- and larger-scale AI methods, there is no such thing as a AI with out Massive Tech.

With vanishingly few exceptions, each startup, new entrant, and even AI analysis lab relies on these corporations. These with the cash make the principles. And proper now, they’re engaged in a race to the underside, releasing methods earlier than they’re prepared in an try to retain their dominance. Learn the complete story.

I obtained the brand new gene-editing drug for sickle cell illness. It modified my life.

—By Jimi Olaghere, a affected person advocate and tech entrepreneur

In the future a couple of years in the past, I obtained a package deal that may change my life. It was from Vertex Prescription drugs, and it contained a consent type to take part in a scientific trial for a brand new gene-editing drug to deal with sickle cell illness.

I’d lived with sickle cell my complete life—experiencing persistent ache, organ harm, and hopelessness. To me, this chance meant lastly taking management of my life.

The drug I obtained, referred to as exa-cel, might quickly turn into the primary CRISPR-based remedy to win approval from the US Meals and Drug Administration. However many individuals who want these remedies could by no means obtain them. Learn the complete story.